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INT131(formerlyT0903131,T131,AMG131)isapotentnon-thiazolidinedione(TZD)selectiveperoxisomeproliferator-activated
receptor γ modulator (SPPARM) currently in Phase 2 clinical trials for treatment of type-2 diabetes mellitus (T2DM). This new
chemical entity represents a second generation SPPARM approach developed after the ﬁrst generation PPARγ full agonists to
address their inherent limitations. INT131 was speciﬁcally and carefully designed using preclinical models to exhibit a biological
proﬁle of strong eﬃcacy with de minimis side eﬀects compared to PPARγ full agonists. As a potent PPARγ modulator, INT131
binds to PPARγ with high aﬃnity. In pharmacology models of diabetes and in early clinical studies, it achieved a high level of
eﬃcacy in terms of antidiabetic actions such as insulin sensitization and glucose and insulin lowering, but had little activity in
terms of other, undesired, eﬀects associated with TZD PPARγ full agonists such as edema and adipogenesis. Ongoing clinical
development is directed at translating these ﬁndings into establishing a novel and eﬀective treatment for T2DM patients with an
improved safety proﬁle in relation to that currently available.
Copyright © 2008 L. S. Higgins and C. S. Mantzoros. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. PPARγ FULL AGONISTS
PPARγ fullagonistsareamainstayinthetreatmentofinsulin
resistance and type-2 diabetes. While the glucose lowering
action of thiazolidinediones (TZDs) was well-known as early
as 1988 [1], it was not until 1995 that the nuclear receptor
PPARγ wasidentiﬁedastheirtarget[2]andthatitsactivation
was shown to be responsible for their therapeutic bene-
ﬁts. PPARγ full agonists, including the TZDs rosiglitazone
(Avandia) and pioglitazone (Actos) are powerful drugs for
the treatment of insulin resistance associated with type-2
diabetes mellitus (T2DM) [3]. Troglitazone (Rezulin) was
the ﬁrst TZD approved for clinical use in the US in 1997, but
was subsequently withdrawn from the market in 2000 due to
idiosyncratic hepatotoxicity. Rosiglitazone and pioglitazone
were approved in the US in 1999. These drugs enabled the
beneﬁcial eﬀect of PPARγ activating agents to be recognized
in clinical practice globally.
Thesemedicationsenhanceinsulinsensitivityandreduce
glucose and insulin levels in T2DM patients, and have been
shown to have robust and relatively durable beneﬁt for glu-
cose control [4]. Insulin resistance is a key etiologic feature
in the onset and subsequent progression of the disease.
Furthermore, insulin sensitization comprises a complemen-
tary mechanism of action to that of other commonly used
therapeutic modalities such as inhibition of gluconeogenesis
by metformin, increased insulin secretion by sulfonylureas,
and administration of exogenous insulin. The potential
to be used in combination with other approaches thus
further extends the clinical utility of PPARγ activating agents
for glucose control and to treat T2DM. Rosiglitazone and
pioglitazone, both in the TZD class, are the only agents
currently approved for insulin sensitization as their major
mechanism of action.
Realization of PPARγ maximal therapeutic potential by
full agonists is limited, however, by associated side eﬀects.
PPARγ full agonist binding to PPARγ activates a broad
spectrum of PPARγ mediated eﬀects, some of which are
undesirable. Thus, use of TZDs is limited by side eﬀects
that include weight gain, ﬂuid retention, and decreased2 PPAR Research
bone density [5]. TZD-induced peripheral edema, which
frequently occurs in patients receiving TZD monotherapy,
is especially problematic in patients receiving concomitant
insulin therapy, and is of special concern for patients who
have either clinical or subclinical congestive heart failure
(CHF) and thus cannot tolerate the extra ﬂuid volume
[6, 7]. In addition, there is strong evidence that activation
of PPARγ causes adipocyte diﬀerentiation and increased
adipose tissue mass, contributing to weight gain [3]. The
dose response curve for the therapeutic eﬀects of TZDs
overlaps with the dose response for side eﬀects, such that
increasing doses produce both greater beneﬁts for glucose
control as well as greaterincidence and higher degrees of side
eﬀects [8]. Thus, doses which would produce the maximal
clinical beneﬁt of PPARγ full agonists may not be tolerated
by a signiﬁcant number of patients and the full potential
of PPARγ activation for insulin sensitization and glucose
control may not be realized at approved clinical doses of
rosiglitazone or pioglitazone.
As a consequence of the known safety issues, TZDs
are not recommended for patients with New York Heart
Association Class 3 and 4 CHF, and the potential clinical
impact of cardiovascular side eﬀects prompted the American
Heart and the American Diabetes Associations to issue a
joint consensus statement advising against the use of TZDs
in patients with advanced heart failure [9]. Awareness of
the safety issues associated with TZDs was dramatically
increasedfollowingthepublicationofameta-analysisinMay
of 2007 showing a nonstatistically signiﬁcant trend towards
an increase in macrovascular events in patients taking
rosiglitazone [10]. As a result of a detailed examination
of the safety record for the TZD class, both rosiglitazone
and pioglitazone received black box safety warnings for
the increased risk of CHF due to ﬂuid retention. Only
rosiglitazone was further implicated for a “possible” risk of
increased ischemic cardiovascular events [11] and obtained
anadditionalblackboxwarning,butdatasuggestingthisrisk
have not been replicated by all studies. Finally, a series of sci-
entiﬁc papers has demonstrated an association between TZD
use and bone fracture, especially in women [12]. Despite
these well-known limitations, Actos and Avandia represent
a combined annual global market of more than $5 billion
evenfollowingarapiddecreaseandthenstabilizationoftotal
sales and a switch from rosiglitazone to pioglitazone or other
antidiabetic medications following heightened awareness of
safety concerns in 2007. The continued use of the TZDs is
a strong testament to the utility of insulin sensitization as a
mode of action for treatment of T2DM, but also underscores
the need for a safer treatment for insulin resistance.
Historically, the proven therapeutic utility of activating
the PPARγ nuclear receptor to reduce glucose and HbA1c
led the pharmaceutical industry to focus on a search for
gr eat e randb r oad e re ﬃcacythrough morepotent PPARγ full
agonists as well as through the development of dual α and γ
(“α/γ”) PPAR agonists. The latter were intended to combine
the insulin sensitizing eﬀects of PPARγ activation with the
lipid lowering eﬀects of PPARα activation. Unfortunately,
no new agents deriving from these programs have been
approved for clinical use. In the case of full PPARγ agonists,
eﬃcacy and side eﬀects have been shown to be intrinsically
linked, with higher eﬃcacy compounds associated with
greater propensity for side eﬀects. Similarly, PPARα/γ dual
agonists have been plagued with side eﬀects. For example,
muraglitazar, a dual PPARα/γ agonist, was taken through
a comprehensive development program and demonstrated
remarkable eﬃcacy in lowering HbA1c as well as improving
lipid proﬁle in T2DM patients. However, preclinical and
clinical safety signals associated with edema, weight gain,
and increased cardiovascular events led to a request in
2005 by FDA for outcome studies prior to approval and
resulted in abandonment of the program by the sponsor
in 2006. In summary, accumulated experience with PPARγ
and PPARα/γ ligands has led to an understanding of a spec-
trum of desirable and undesirable activities, as graphically
depicted in Figure 1.
2. SELECTIVE PPARγ MODULATION
SEPARATES EFFICACY AND SIDE EFFECT
DOSE REPONSE CURVES
Av e r yd i ﬀerent approach to leveraging PPARγ antidiabetic
therapeutic beneﬁts would focus on minimizing side eﬀects
(Figure 1, left) by limiting the spectrum of activation. This
approach would require selective PPARγ modulation which
by design would minimize side eﬀects while maintaining
desired therapeutic beneﬁt.
After the identiﬁcation of PPARγ as the target for
TZDs, the crystal structure of the PPARγ binding pocket
as well as its activity relationships were probed, providing
an important tool for pursuing selective modulation of the
receptor. For example, in the case of the TZD PPARγ full
agonists, a key interaction occurs between the ligand and
the activation helix (helix 12) of PPARγ [13, 14]. Binding
of activating ligands to the nuclear receptor PPARγ leads
to conformational changes favoring binding of PPARγ to
the RXR nuclear receptor, which is required for PPARγ
driven gene transcription, as well as to altered association
with cofactors (Figure 2). Diﬀerent types of PPARγ ligands
lead to suﬃciently diﬀerent conformations of the bound
receptor heterodimer complex that diﬀerent combinations
and patterns of coactivators and corepressors are recruited
for diﬀerential transcriptional control [15]. That is, the
composition of the protein complex of PPARγ,R X R ,a n d
speciﬁc cofactors determines the pattern of the ensuing
gene transcription and hence the cellular response to the
PPARγ ligand. Since the repertoire of cofactors available
for recruitment to the PPARγ-RXR complex varies among
cell types, PPARγ responses are context-dependent. Thus,
full agonists such as TZDs would be expected to lead to a
diﬀerent pattern of cofactor recruitment, gene transcription,
and cellular response than a SPPARM.
Theoretically, SPPARMs can be identiﬁed or designed
which would produce a pattern of cofactor recruitment,
gene transcription, and cellular response whereby the dose
response curves for desired and undesired eﬀects seen
in patients could potentially be suﬃciently separated to
establish a broad therapeutic window (Figure 3). Is there
precedence for the success of a modulator approach forL. S. Higgins and C. S. Mantzoros 3
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Figure 1: Spectrum of PPARγ eﬀects. The range of biological activities, both desired antidiabetic therapeutic eﬀects and undesired eﬀects
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Figure 2: PPARγ activation. Upon ligand binding, the nuclear receptor PPARγ associates with nuclear receptor RXR as well as with
coactivators and corepressors which are present in a cell type and state speciﬁc pattern. This complex binds to PPAR response elements
to enhance or repress gene transcription.
another nuclear receptor? Both tamoxifen and its succes-
sor raloxifene are selective estrogen receptor modulators
(SERMs) which are designed to optimize the therapeutic
actions of estrogen receptor activation while minimizing the
side eﬀects [16]. A number of SPPARMs have to date been
identiﬁed by in vitro and preclinical studies and some have
entered early clinical studies [11, 14]b u tn or e p o r t sh a v e
been published on any of these molecules reaching advanced
stages of clinical development.
3. INT131 SPECIFIC DESIGN AND DEVELOPMENT FOR
MOLECULAR AND IN VITRO SPPARM ACTIVITY
INT131 (formerly T0903131, T131, AMG131) was devel-
oped focusing on a strategy to design a SPPARM which
would bind to PPARγ with high aﬃnity but could potentially
activate only a subset of the full spectrum of activities.
Such a speciﬁcally designed molecule would thereby retain
the antidiabetic actions of full PPARγ agonists such as
rosiglitazone and pioglitazone but would have minimal, if
any, side eﬀects (including weight gain and ﬂuid retention)
caused by these TZDs. In fact, a primary screening assay
assed only moieties which antagonized roziglitazone induced
activityassociatedwithsideeﬀectsINT131wasthusdesigned
and developed as a non-TZD PPARγ modulator which
represents a new chemical class of PPARγ ligands. INT131
binds to PPARγ within the same binding pocket as the
TZDs, but occupies a unique space in the pocket and
contacts the receptor at distinct points from the TZDs [17].
Importantly, the interaction with the activation helix of
PPARγ by INT131 and by TZDs diﬀers. The net result of the
diﬀerent binding by the two types of ligands is alternative
conformationalchangeofPPARγ,leadingtodistinctpatterns
of association with cofactors by this nuclear receptor, and
thus ultimately to unique patterns of gene transcription
[15, 17].
INT131 binds to PPARγ and displaces rosiglitazone
with a Ki of ∼10nM [17], demonstrating ∼20-fold higher
aﬃnity than either rosiglitazone or pioglitazone [18], and
with greater than 1000-fold selectivity for PPARγ over
PPARα,P P A R δ, or a set of other nuclear receptors [17].
CharacterizationbeyondbindingrevealsthatselectedPPARγ
receptor activities are induced by INT131. In a cell-based
reporter assaydesigned todetectfullagonistactivity, INT131
activates PPARγ with an eﬃcacy of only about 10% of
that of rosiglitazone (Figure 4(a)). Similarly, in ﬂuorescence4 PPAR Research
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activity (eﬃcacy, bottom) compared to a full agonist. Hence, increasing concentration (or dose) may lead to increases in some responses
without linked increases in others. This oﬀers the potential in the clinical setting for separation of antidiabetic eﬃcacy from side eﬀects such
as edema and weight gain.
resonance energy transfer assays, INT131 causes recruitment
of coactivator DRIP205, which is important for adipocyte
diﬀerentiation, with an eﬃcacy of about 20–25% of that
of a set of full agonists including rosiglitazone, pioglita-
zone, and troglitazone (Figure 4(b)). Consistent with its
high potency, selective activity proﬁle in the full agonist
cell-based reporter and FRET assays, INT131 causes little
adipocyte diﬀerentiation or triglyceride accumulation in
cultured mouse (Figure 4(c)) or human preadipocytes [17,
19]. Moreover, INT131 blocks most of the potent eﬀects
of rosiglitazone to promote fat cell diﬀerentiation [17].
Thus, INT131 shows selectivity among the full spectrum
of PPARγ eﬀects and has the desired, nonadipogenic pro-
ﬁle.
PPARγ activation by a SPPARM is predicted to be
context-dependent. Maximal activity of INT131 is sensitive
to cellular environment of PPARγ. That is, using the same
reporter construct and assay designed to detect PPARγ full
agonist activity, INT131 potency and eﬃcacy may be less
than, equal to, or greater than the comparator full agonists
rosiglitazone depending on the host-cell type (Figure 5).
4. PHARMACOLOGY OF INT131 IS CONSISTENT
WITH SPPARM ACTIVITY
INT131 is potent and highly eﬃcacious in animal models
o fd i a b e t e s ,b u tc a u s e sm u c hl e s sw e i g h tg a i na n dv o l u m e
expansion than marketed TZDs. For example, in Zucker
fatty rats, a standard rodent model of T2DM, INT131 was
more potent than rosiglitazone in reducing serum glucose
(Figure 6), insulin, triglyceride, and NEFA concentrations
and in improving glucose tolerance [17]. Notably, INT131
increased levels of the adipokine adiponectin in the Zucker
fatty rat model and in normal rats with equal or greater
potency than does rosiglitazone (Figure 7). Adiponectin
levels are suppressed in obesity and in T2DM, and increased
adiponectin production is thought to be a key mediatorL. S. Higgins and C. S. Mantzoros 5
0
30
60
90
120
R
e
l
a
t
i
v
e
e
x
p
r
e
s
s
i
o
n
l
e
v
e
l
(
n
o
r
m
a
l
i
z
e
d
t
o
r
o
s
i
g
l
i
t
a
z
o
n
e
)
−6 −5 −4 −3 −2 −10 1 2
Log[compound] (μM)
Rosiglitazone
Pioglitazone
Troglitazone
Farglitazar
BPx
INT131
(a)
0
20
40
60
80
100
120
R
e
l
a
t
i
v
e
H
T
R
F
u
n
i
t
s
−4 −3 −2 −10 1
Log[compound] (μM)
Rosiglitazone
Pioglitazone
Troglitazone
Farglitazar
Netoglitazone (MCC555)
INT131
(b)
0
2.5
5
7.5
10
12.5
15
L
i
p
i
d
a
c
c
u
m
u
l
a
t
i
o
n
(
r
e
l
a
t
i
v
e
t
o
c
o
n
t
r
o
l
)
−6 −5 −4 −3 −2 −10 1 2
Log[compound] (μM)
Rosiglitazone
Pioglitazone
Troglitazone
Farglitazar
BPx
INT131
(c)
Figure 4: PPARγ full agonists, but not INT131, activate expression of a full agonist reporter gene, induce recruitment of DRIP205 coactivator
peptide to PAPRγ, and cause lipid accumulation. (a) An expression construct bearing a PPAR response element designed to be activated
by PPARγ full agonists was used to detect reporter gene expression. Transfected HEK cells were exposed to a range of concentrations
of the indicated PPAR ligands, and expression measured. The maximal expression stimulated by INT131 was about 10% that promoted
by rosiglitazone, pioglitazone, troglitazone, farglitazar, and BPx. (b) A homogenous time-resolved ﬂuorescence energy transfer (FRET)
assay was used to measure association of a DRIP205 coactivator peptide to PPARγ upon exposure to a range of concentrations of
the indicated PPAR ligands. The maximal association stimulated by INT131 was about 20–25% that was promoted by rosiglitazone,
pioglitazone, troglitazone, farglitazar, and netoglitazone. (c) Lipid accumulation was measured in murine preadipocytes exposed to a range
of concentrations of the indicated PPAR ligands. The maximal lipid accumulation stimulated by INT131 was about 10% that was promoted
by rosiglitazone, pioglitazone, troglitazone, farglitazar, and BPx, Data on ﬁle.
for the insulin sensitizing and anti-inﬂammatory eﬀects of
PPARγ [20].
In a variety of animal models, full agonists cause ﬂuid
retention and increased heart weight, probably as a result
of the increased cardiac load caused by plasma volume
expansion. As expected, administration of rosiglitazone to
Zucker diabetic fatty rats for two weeks caused a sig-
niﬁcant decrease in hematocrit, a marker for increased
plasma volume expansion (Figure 8(a)); increase in heart
weight(Figure 8(b));andincreasedlungweight(Figure 8(c))
consistent with a secondary eﬀect to cardiac hypertrophy
and developing CHF. INT131 at the same supratherapeutic
dose did not cause these eﬀects. Thus, SPPARM activity is
observedinthisrodentmodelofT2DM,andtheantidiabetic6 PPAR Research
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Figure 5: PPARγ activation by INT131 is cell-type-dependent. Cell-based reporter assays were performed by transfecting three diﬀerent cell
types (HEK293, CV-1, CHO) with the same reporter construct and stimulating with increasing concentrations of rosiglitazone (black) or
INT131 (red). Adapted from [17].
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eﬀects of PPAR activation have been separated from ﬂuid
retention and adverse cardiac eﬀects.
5. TOXICOLOGYOF INT131 DEMONSTRATES
A SAFETY PROFILE DISTINCT FROM TZDs AND
CONSISTENT WITH A SPPARM
Preclinical safety experience with PPARγ full agonists has
produced a consistent proﬁle of target mediated eﬀects.
Prominent among these are: ﬂuid retention as manifested
by a drop in hematocrit and related hematological measures
of increased plasma volume as well as in edema; weight
gain due to increased adipose tissue together with ﬂuid
retention; cardiac hypertrophy and heart failure; and fatty
inﬁltration and replacement of bone marrow. Appearance
of these adverse eﬀects follows a predictable steep time
and dose relationship in multiple species (Figure 9,[ 21]),
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following either INT131 or rosiglitazone treatment.Z u c k e rf a t t y
rats were treated orally with the indicated dose of INT131 or
rosiglitazone once daily for 15 days, and plasma adiponectin was
measured. P<0.05 compared to vehicle group adapted from
[17, 19].
and has been predictive of clinical experience. Therefore,
preclinical results from subchronic and chronic safety
studies take on heightened importance for PPAR ligands
in clinical development. Based on experience with many
PPAR full agonist programs, the 2008 FDA draft guidance
for development of diabetes drugs [22] includes speciﬁc
recommendations for preclinical studies with PPAR ligands.
These include detailed measures to detect cardiac changes,
fatty inﬁltration of organs, and ﬂuid retention. According to
the draft guidance, appearance of safety signals in preclinical
programs which have been predictive of clinical safety issues
for other PPAR ligands could lead to a requirement for more
detailed clinical safety studies or outcome studies prior to
approval.
INT131 is well tolerated in rats treated for 6 months with
doses resulting in up to two to three orders of magnitude
greaterexposurethanexposureattainedateﬃcaciousclinicalL. S. Higgins and C. S. Mantzoros 7
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Figure 8: INT131 does not increase plasma volume, heart weight, or lung weight. Zucker fatty rats were treated orally once daily for 14 days
with 80mg/kg/day of INT131 or rosiglitazone (n = 6/group). (a) Hematocrit, (b) heart weight, and (c) lung weight were measured, and
organ weights normalized to body weight. Adapted from [17, 19].
doses in humans. Of particular note was the lack of the
toxicities characteristic of PPARγ full agonists, including
signs of ﬂuid accumulation or increased heart weight at
doses representing these high safety multiples. These adverse
eﬀects are typically observed at or near eﬃcacious exposure
levels for potent PPARγ full agonists. Thus, the therapeutic
window for INT131 is predicted to be signiﬁcantly greater
than it is for the older classes of compounds.
Safety testing of INT131 in cynomolgus monkeys for
one and six months at exposures up to >70-fold (highest
dose and duration tested) over the exposures expected at the
highest dose in the ongoing clinical development program
showed that all doses were well tolerated. Conﬁrming the
rat safety study results, typical PPAR full agonist eﬀects such
as ﬂuid retention, increased adiposity, fatty replacement of
marrow, or cardiac changes detected by echocardiography,
pathology, or histology were not observed in INT131 treated
monkeys.
An additional area of concern for the general PPAR
ligand class of compounds is carcinogenicity. In July 2004,
FDA provided guidance regarding preclinical and clinical
safety assessments for any molecules in clinical development
aﬀecting PPAR superfamily members. Cumulative rodent
data reviewed by the agency for a number of PPARγ dual α/γ
agonists in development had shown an increased incidence
of carcinogenicity. Based on these data, the FDA mandated
that clinical dosing could not exceed six months with any
PPAR ligand (α, γ, δ, α/γ dual, or α/γ/δ pan agonist) unless
two-year rodent carcinogenicity studies were completed and
satisfactorily reviewed by the agency.
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Figure 9: Preclinical LOAEL for PPARγ full agonists follows a steep
timedependence.Thelowestobservableadverseeﬀectlevel(LOAEL)
at various exposure times in mouse, rat, and monkey is depicted
for aggregate data for the class and expressed as multiple of clinical
exposure level. Data from [21].
agonists and dual PPARα/γ agonists (Figure 10) for several
reasons. First, many of the PPAR binding molecules that
caused tumors in the rodent studies were PPARα/γ dual
agonist with which multispecies, multitissue, and both-sex
tumorincidenceoccurred[23].INT131ishighlyselectivefor8 PPAR Research
Carcinogenicity risk appears correlated with full spectrum PPAR activity
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Figure 11: Adiponectin level is stimulated in human subjects
exposed to INT131. Circulating adiponectin was measured in
healthy volunteers exposed to 8 consecutive daily ﬁxed oral doses
of INT131. Adapted from [24].
PPARγ, with no binding to PPARα or δ at 10μM, 1000 fold
over the Ki for PPARγ [19].
While carcinogenicity is less of a concern for PPARγ
agonists than for PPARα or α/γ dual agonists, the two
most prevalent types of tumors associated with PPARγ
full agonist molecules which do occur are lipomas and
hemangiosarcomas.Thesecancersderivefromadiposetissue
and vascular endothelium, respectively. Since INT131 shows
littlepropensitytopromoteadipocytediﬀerentiationinvitro
or adipose proliferation in vivo, it would be reasonable
to expect that INT131 would convey minimal, if any, risk
for these malignancies. Similarly, the lack of edema in
preclinical models suggests a weak activity in the vascular
endothelium and thus would be unlikely to invoke the
activation associated with hemangiosarcomas at very high
doses of full PPARγ agonists. Taken together, it is likely that
selectivity of a SPPARM such as INT131 will reduce the
potential for carcinogenicity that plague PPAR full agonists,
butthisremainstobeconclusivelyshownbyongoingstudies.
6. EARLY CLINICAL RESULTS WITH INT131 SHOW
SEPARATION OF EFFICACY FROM SIDE EFFECTS
Four Phase 1 studies have demonstrated that INT131
besylate is well tolerated and has highly desirable pharma-
cokinetic and pharmacodynamic properties. The rapid and
robust stimulation of adiponectin levels (Figure 11)p r o vi d e s
evidence of activation of PPARγ pathways associated with
therapeutic eﬃcacy, conﬁrming preclinical pharmacology
results [15].
A 4-week Phase 2a multicenter, randomized, double
blind, placebo controlled study was conducted to establish
the glucose lowering activity of INT131 besylate in subjects
with T2DM. INT131 was well tolerated, with no signiﬁcant
safety signals [19]. A reduction in fasting plasma glucose
(the primary endpoint of the study) was observed at week
1 and week 4, unusually early for this mechanism of action,
and was statistically signiﬁcant despite the short duration
of treatment. Stimulation of adiponectin levels, seen in
healthy volunteers in Phase I, was conﬁrmed in the T2DM
population in the Phase 2a study. Most notably, the SPPARM
activity of INT131 was supported by separation of the
observed antidiabetic eﬀects from edema and weight gain,
diﬀerentiating INT131 from TZD PPARγ full agonists. These
results provided the foundation for an ongoing multicenter
double blind placebo controlled Phase 2b study of 4 doses
of INT131 and pioglitazone comparator in T2DM patients,
which is designed to rigorously test the SPPARM activity of
INT131forseparationofPPARγmediatedeﬃcacyintreating
insulin resistance from TZD side eﬀects.
7. CONCLUSION
The non-TZD selective PPARγ modulator INT131 is the
culmination of a molecular target-based strategy to develop
an improved insulin-sensitizing drug that does not cause theL. S. Higgins and C. S. Mantzoros 9
weight gainand edema thatplague the PPAR fullagonists. As
predicted by its unique PPARγ proﬁle, INT131 shows poten-
tial as a potent and eﬃcacious insulin-sensitizing molecule
in T2DM patients that causes little if any weight gain
at therapeutically eﬃcacious doses. This emerging clinical
proﬁle of eﬃcacy/side-eﬀect separation is consistent with the
underlying molecular biology design, the in vitro study data
and the robust preclinical data. It thus represents the ﬁnal
part of an accordant continuum testing the hypothesis that
selectivemodulationofPPARγ cancreateaclinicallyrelevant
therapeutic window which is hoped to eventually provide
tangible beneﬁts to patients.
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